Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...

Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on ...

These findings support the need for a phase III randomized controlled trial to definitively determine whether the addition of an antiangiogenic to a second or even a third-generation TKI provides ...

Radiomics, the extraction of quantitative features from medical images, combined with AI, showed high accuracy in predicting ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

A new study published in the Annals of Surgical Oncology revealed that individuals with little muscle mass, segmentectomy ...

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study ...